1-(4-hydroxy-phenyl)-3-pyridin-3-yl-prop-2-en-1-one | 315681-44-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-hydroxy-phenyl)-3-pyridin-3-yl-prop-2-en-1-one
• 英文别名: (E)-1-(4-hydroxyphenyl)-3-pyridin-3-ylprop-2-en-1-one
• CAS: 315681-44-8
• 化学式: C₁₄H₁₁NO₂
• 分子量: 225.247
• InChiKey: JRNSRWHZOUBRQN-FPYGCLRLSA-N

物化性质

• 沸点：
  438.8±45.0 °C(Predicted)
• 密度：
  1.241±0.06 g/cm3(Predicted)
• 溶解度：
  28.5 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-hydroxy-phenyl)-3-pyridin-3-yl-prop-2-en-1-one 在 potassium carbonate 、 potassium iodide 作用下， 以 丁酮 为溶剂， 反应 96.0h， 生成 ethyl 4-[3-[4-[(E)-3-pyridin-3-ylprop-2-enoyl]phenoxy]propyl]piperazine-1-carboxylate
  参考文献：
  名称：

  Structure–activity relationships of non-imidazole H3 receptor ligands. Part 1

  摘要：

  SAR studies for novel non-imidazole containing H-3 receptor antagonists with high potency and selectivity for rat H-3 receptors are described. A high throughput screening lead, A-923, was further elaborated in a systematic manner to clarify a pharmacophore for this class of aryloxyalkyl piperazine based compounds. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00309-8
• 作为产物：
  描述：

  3-吡啶甲醛 、 对羟基苯乙酮 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 1-(4-hydroxy-phenyl)-3-pyridin-3-yl-prop-2-en-1-one
  参考文献：
  名称：

  新型二硫代氨基甲酸酯-查尔酮衍生物的设计，合成和抗增殖活性研究。

  摘要：

  设计，合成并评估了一系列新颖的二硫代氨基甲酸酯-查耳酮衍生物，针对三种选定的癌细胞系（EC-109，SK-N-SH和MGC-803）具有抗增殖活性。多数合成的化合物对所有测定的癌细胞系均表现出中等至强效的活性。特别地，化合物II2和II5显示出对SK-N-SH的优异的生长抑制，IC 50值分别为2.03μM和2.46μM。进一步的机理研究表明，化合物II2可以通过诱导细胞凋亡并将细胞周期阻滞在G0 / G1期，从而明显抑制SK-N-SH细胞的增殖。

  DOI：

  10.1016/j.bmcl.2016.07.012

文献信息

• Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
  申请人：——

  公开号：US20030166644A1

  公开（公告）日：2003-09-04

  Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

  使用化合物抑制激素敏感性脂肪酶，包括这些化合物的药物组合物，使用这些化合物和组合物的治疗方法，以及新化合物。目前的化合物是激素敏感性脂肪酶的抑制剂，可能在治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病中有用。
• Use of compounds for decreasing activity of hormone-sensitive
  申请人：——

  公开号：US20030166690A1

  公开（公告）日：2003-09-04

  Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

  使用化合物来抑制激素敏感性脂肪酶，包括这些化合物的制药组合物，使用这些化合物和组合物的治疗方法，以及新颖的化合物。这些化合物是激素敏感性脂肪酶的抑制剂，可用于治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病。
• Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
  申请人：Wong C.W. Norman

  公开号：US20060205792A1

  公开（公告）日：2006-09-14

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了一些非天然的多酚化合物，这些化合物可以上调载脂蛋白A-I（ApoA-I）的表达。所述的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关紊乱，例如动脉粥样硬化。
• Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases
  申请人：Wong Norman C.W.

  公开号：US20110082176A1

  公开（公告）日：2011-04-07

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供非自然产生的多酚化合物，可以上调载脂蛋白A-I（ApoA-I）的表达。所披露的组合物和方法可用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关的疾病，例如动脉粥样硬化。
• Synthesis, antiviral activity, 3D-QSAR, and interaction mechanisms study of novel malonate derivatives containing quinazolin-4(3H)-one moiety
  作者：Meihang Chen、Pei Li、Deyu Hu、Song Zeng、Tianxian Li、Linhong Jin、Wei Xue、Baoan Song

  DOI：10.1016/j.bmcl.2015.11.006

  日期：2016.1

  A series of novel malonate derivatives containing quinazolin-4(3H)-one moiety were synthesized and evaluated for their antiviral activities against cucumber mosaic virus (CMV). Results indicated that the title compounds exhibited good antiviral activities. Notably, compounds g15, g16, g17, and g18 exhibited excellent curative activities in vivo against CMV, with 50% effective concentration (EC50) values of 208.36, 153.78, 181.47, and 164.72 mu g/mL, respectively, which were better than that of Ningnanmycin (256.35 mu g/mL) and Ribavirin (523.34 mu g/mL). Moreover, statistically valid three-dimensional quantitative structure-activity relationship (3D-QSAR) models with good correlation and predictive power were obtained with comparative molecular field analysis (CoMFA) steric and electrostatic fields (r(2) = 0.990, q(2) = 0.577) and comparative molecular similarity indices analysis (CoMSIA) with combined steric, electrostatic, hydrophobic and hydrogen bond acceptor fields (r(2) = 0.977, q(2) = 0.516), respectively. Based on those models, compound g25 was designed, synthesized, and showed better curative activity (146.30 mu g/mL) than that of compound g16. The interaction of between cucumber mosaic virus coat protein (CMV CP) and g25 with 1:1.83 ratio is typically spontaneous and exothermic with micromole binding affinity by isothermal titration calorimetry (ITC) and fluorescence spectroscopy investigation. (C) 2015 Elsevier Ltd. All rights reserved.